Skip to content 
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. has strategic collaboration with Boltz, PBC to develop and deploy state-of-the-art biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. more
| Time Frame | PFE | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 7.14% | 1.44% | 0.64% |
| 1-Month Return | 9.26% | -0.67% | -0.17% |
| 3-Month Return | 13.2% | 6.14% | 1.88% |
| 6-Month Return | 12.33% | 19.98% | 9.19% |
| 1-Year Return | 6.73% | 6.85% | 14.76% |
| 3-Year Return | -37.08% | 17.99% | 70.19% |
| 5-Year Return | -20.52% | 34.54% | 77.96% |
| 10-Year Return | -1.32% | 142.13% | 275.69% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 81.29B | 100.33B | 59.55B | 63.63B | 62.58B | [{"date":"2021-12-31","value":81.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.36,"profit":true},{"date":"2024-12-31","value":63.42,"profit":true},{"date":"2025-12-31","value":62.37,"profit":true}] |
| Cost of Revenue | 34.41B | 38.24B | 29.21B | 21.78B | 18.57B | [{"date":"2021-12-31","value":89.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.39,"profit":true},{"date":"2024-12-31","value":56.96,"profit":true},{"date":"2025-12-31","value":48.55,"profit":true}] |
| Gross Profit | 46.88B | 62.09B | 30.34B | 41.85B | 44.01B | [{"date":"2021-12-31","value":75.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":48.86,"profit":true},{"date":"2024-12-31","value":67.4,"profit":true},{"date":"2025-12-31","value":70.89,"profit":true}] |
| Gross Margin | 57.67% | 61.89% | 50.95% | 65.77% | 70.33% | [{"date":"2021-12-31","value":81.99,"profit":true},{"date":"2022-12-31","value":87.99,"profit":true},{"date":"2023-12-31","value":72.44,"profit":true},{"date":"2024-12-31","value":93.51,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Expenses | 26.08B | 24.54B | 25.05B | 25.36B | 28.58B | [{"date":"2021-12-31","value":91.27,"profit":true},{"date":"2022-12-31","value":85.88,"profit":true},{"date":"2023-12-31","value":87.65,"profit":true},{"date":"2024-12-31","value":88.75,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 20.79B | 37.55B | 5.29B | 16.48B | 15.44B | [{"date":"2021-12-31","value":55.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":14.09,"profit":true},{"date":"2024-12-31","value":43.9,"profit":true},{"date":"2025-12-31","value":41.11,"profit":true}] |
| Total Non-Operating Income/Expense | 2.26B | (3.81B) | (4.82B) | (11.01B) | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-168.23,"profit":false},{"date":"2023-12-31","value":-212.95,"profit":false},{"date":"2024-12-31","value":-486.35,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 24.31B | 34.73B | 1.06B | 8.02B | 7.52B | [{"date":"2021-12-31","value":70,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.05,"profit":true},{"date":"2024-12-31","value":23.1,"profit":true},{"date":"2025-12-31","value":21.65,"profit":true}] |
| Income Taxes | 1.85B | 3.33B | (1.11B) | (28.00M) | (266.00M) | [{"date":"2021-12-31","value":55.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-33.47,"profit":false},{"date":"2024-12-31","value":-0.84,"profit":false},{"date":"2025-12-31","value":-7.99,"profit":false}] |
| Income After Taxes | 22.46B | 31.40B | 2.17B | 8.05B | - | [{"date":"2021-12-31","value":71.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.92,"profit":true},{"date":"2024-12-31","value":25.64,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 22.46B | 31.40B | 2.17B | 8.05B | - | [{"date":"2021-12-31","value":71.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.92,"profit":true},{"date":"2024-12-31","value":25.64,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | (434.00M) | 6.00M | - | - | - | [{"date":"2021-12-31","value":-7233.33,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 22.15B | 31.36B | 2.13B | 8.02B | 7.77B | [{"date":"2021-12-31","value":70.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.8,"profit":true},{"date":"2024-12-31","value":25.57,"profit":true},{"date":"2025-12-31","value":24.77,"profit":true}] |
| EPS (Diluted) | 4.42 | 6.58 | 1.58 | 3.11 | 2.96 | [{"date":"2021-12-31","value":67.17,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":24.01,"profit":true},{"date":"2024-12-31","value":47.26,"profit":true},{"date":"2025-12-31","value":44.98,"profit":true}] |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PFE | |
|---|---|
| ROA (LTM) | 5.19% |
| ROE (LTM) | 8.58% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PFE | |
|---|---|
| Trailing PE | 20.01 |
| Forward PE | 9.29 |
| P/S (TTM) | 2.47 |
| P/B | 1.67 |
| EV/R | 3.21 |
| EV/Ebitda | 13.32 |
| PEG | 3.77 |
Pfizer Inc (PFE) share price today is $27.61
Yes, Indians can buy shares of Pfizer Inc (PFE) on Vested. To buy
Yes, you can purchase fractional shares of Pfizer Inc (PFE) via the Vested app. You can start investing in Pfizer Inc (PFE) with a minimum investment of $1.
You can invest in shares of Pfizer Inc (PFE) via Vested in three simple steps:
The 52-week high price of Pfizer Inc (PFE) is $27.37. The 52-week low price of Pfizer Inc (PFE) is $19.5.
The price-to-earnings (P/E) ratio of Pfizer Inc (PFE) is 20.0147
The price-to-book (P/B) ratio of Pfizer Inc (PFE) is 1.67
The dividend yield of Pfizer Inc (PFE) is 6.49%
The market capitalization of Pfizer Inc (PFE) is $153.80B
The stock symbol (or ticker) of Pfizer Inc is PFE
Consider the share price of Pfizer Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Pfizer Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Pfizer Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Pfizer Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Pfizer Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Pfizer Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
